MoonLake reports 24-week PsA data with ~60% ACR50; plans Phase 3 HS trials in Q2 2024

MoonLake Immunotherapeutics

ARGO trial: ~60% ACR50 at week 24; ~40% ACR70; >80% PASI90; ~60% PASI100; low discontinuation ~5%.
Composite responses: ACR50+PASI100 up to 52%, MDA up to 61%; sonelokimab outperformed adalimumab.
Regulatory feedback from FDA/EMA supports Phase 3 HS program (VELA) enrolling 800 patients; top-line data expected mid-2025.
US real-world data: 2M diagnosed HS patients; market opportunity >$10B by 2035; low biologic penetration ~3%.
Four additional clinical trials imminent in new indications (palmo-plantar pustulosis, juvenile HS, seronegative SpA).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.